( January 23, 2025, 1:46 PM EST) -- WASHINGTON, D.C. — For the second time in recent weeks, the Federal Circuit U.S. Court of Appeals on Jan. 22 affirmed a finding by the U.S. Patent Trial and Appeal Boar (PTAB) that a biopharmaceutical company’s in utero DNA testing product was not shown to be unpatentable in an inter partes review (IPR) proceeding....